Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expression

Written by Kirsten Ruehl on 5th June 2023. Posted in Client News.

• Previous
• Next